Enterprise Value
3.246B
Cash
375.4M
Avg Qtr Burn
-8.578M
Short % of Float
6.57%
Insider Ownership
0.49%
Institutional Own.
99.19%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NUPLAZID® (pimavanserin) (serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors) Details PDP (Parkinsons disease psychosis) | Approved Quarterly sales | |
DAYBUE™ (Trofinetide ) Details Rett syndrome | Approved Quarterly sales | |
sNDA FDA meeting | ||
ACP-101 (intranasal carbetocin) Details Prader-Willi syndrome | Phase 3 Data readout | |
Pimavanserin (serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors) Details Schizophrenia Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
ACP-204 Details Alzheimer's disease | Phase 2/3 Data readout | |
ACP-044 Details Pain, Post operative acute pain | Failed Discontinued |